Scientific Advisory Board

Chris Becker, Ph.D., Scientific Advisor and Co-founder. Dr Becker is a co-founder of Protein Metrics and he was the Company’s first President and CEO.  In January of 2017 Dr Becker retired as President and CEO to become a Scientific Advisor for the Company.  Dr. Becker has over 20 years of management experience at SRI International, GeneTrace, Thermo Fisher Scientific, and PPD, Inc.  He has over 30 years of experience in mass spectrometry and chemical physics.  His research has included the original development of label-free protein quantification, protein biomarker discovery, and rapid DNA analysis.  Dr. Becker received his Ph.D. from UC Berkeley and was a post-doc in chemistry and physics at MIT.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

Matt Croughan, Ph.D

Professor Matt Croughan, Ph.D.  Matt Croughan, Ph.D. is the George B. and Joy Rathmann Professor and Director of the Amgen Bioprocessing Center at Keck Graduate Institute (KGI) in Claremont, CA, USA. In 2006, he founded the Bioprocessing focus track at KGI and, with the help of colleagues from industry who often serve as adjunct professors, has built it into one of the largest masters-level programs in bioprocessing, with a unique emphasis on recruiting and educating the next generation of business leaders in bioprocessing. He teaches several graduate courses and advises approximately 50 graduate students specializing in various areas of bioprocessing.

Prior to joining KGI, and still one day per week, Dr. Croughan works as an independent consultant providing expert guidance on biopharmaceutical process development and manufacturing to over fifty-five firms. Previously Dr. Croughan was the chief scientist for Genentech’s cell culture facility in Vacaville, CA, built for the production of therapeutic antibodies. Dr. Croughan also led the development of a new licensed cell culture process for Activase, eliminating all animal-derived raw materials and tripling productivity. Earlier in his career at Genentech, he developed the first high-density, fed-batch animal cell culture process, a breakthrough platform technology now used throughout the biopharmaceutical industry. Matt has a Ph.D. from MIT and a BS from UC Berkeley, both in chemical engineering. He is a Fellow of the American Institute of Medical and Biological Engineers (top 2% of engineers in US).

David Vetterlein, Ph.D.

David Vetterlein, Ph.D.  David Vetterlein, Ph.D., brings over 30 years of biotechnology experience in the areas of bioprocessing and protein manufacturing. Most recently, Dr. Vetterlein worked in numerous capacities at ICOS Corporation. At ICOS, he built a clinical manufacturing facility and developed the infrastructure needed to support a pipeline of biologic products at a production scale of up to 3,000L. This included hiring and staff management for process engineering, project management, upstream and downstream process development and cGMP manufacturing through Phase III development in preparation for commercial launch. Additionally, Dr. Vetterlein established a very successful contract manufacturing business at ICOS, completing more than 25 different projects from yeast, CHO and E.coli origin and developing many novel biologic manufacturing processes and characterization methods. In 2007, the ICOS biologics division was sold to CMC Biopharma of Copenhagen and Dr. Vetterlein became Chief Science Officer, focusing on process troubleshooting, originating new process technologies, and establishing the conceptual design for a large-scale commercial manufacturing facility.

Prior to ICOS, Dr. Vetterlein worked at Genentech, Inc. for 10 years as a Senior Scientist where he developed processes for manufacturing of vaccines, antibodies and other proteins. He is a member of the Amgen Bioprocess Advisory Board at Keck Graduate Institute of Applied Life Sciences in Claremont, CA and in 2009 he became an adjunct faculty member. Dr. Vetterlein earned in Ph.D. in Biology (Biochemistry) from the University of California at Santa Barbara, where he utilized biophysical methods to study the kinetic and allosteric properties of a cytoplasmic enzyme. Dr. Vetterlein has been consulting in the area of Biologics Process Development, CMO Arrangements and GMP Manufacturing since November 2008.

David Fenyö, Ph.D.

Professor David Fenyö, Ph.D.  David Fenyö, Ph.D. is an Associate Professor in the Department of Biochemistry and the Center for Health Informatics and Bioinformatics at New York University Langone Medical Center, and Head of the Computational Proteomics Laboratory. Since receiving his Ph.D. in physics from Uppsala University in Sweden in 1991, he has been co-founder of a bioinformatics startup, Director of Proteomics at Genomic Solutions, Staff Scientist at GE Healthcare and Amersham Biosciences, and Senior Research Associate at The Rockefeller University. Dr. Fenyö has over 20 years of experience with all aspects of proteomic and mass spectrometric data analysis in both academia and industry. During these years, he has laid a statistical foundation for testing the significance of protein identification results, developed search engines that identify proteins by matching mass spectrometric and sequence data, and built commercial software packages for fully automatic high-throughput identification and quantitation of proteins. He has more than 80 scientific publications in these areas.

Dr. Fenyö’s research goal is detailed understanding of the dynamics of cellular processes. He applies mathematical, statistical and computational methods to experimental design optimization, quantitative data analysis, and biological systems modeling. The focus of his research is proteomic data analysis: he develops methods and databases for protein identification, characterization and quantitation using mass spectrometry-based technologies. Dr. Fenyö also publishes proteomics news on his twitter account @CompProteomics.